AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Condition.
On May 1, 2017, we issued a press release announcing that we had
cash and cash equivalents of $2.2 million as of March31, 2017.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
| 99.1 |
Press release issued by AmpliPhi Biosciences Corporation on May 1, 2017 |
|
About AmpliPhi Biosciences Corporation (NYSEMKT:APHB)
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates include AB-SA01, AB-PA01 and AB-CD01. AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Recent Trading Information
AmpliPhi Biosciences Corporation (NYSEMKT:APHB) closed its last trading session down -0.23 at 2.42 with 1,249,075 shares trading hands.
